JP2017528516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528516A5 JP2017528516A5 JP2017528760A JP2017528760A JP2017528516A5 JP 2017528516 A5 JP2017528516 A5 JP 2017528516A5 JP 2017528760 A JP2017528760 A JP 2017528760A JP 2017528760 A JP2017528760 A JP 2017528760A JP 2017528516 A5 JP2017528516 A5 JP 2017528516A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- statin
- particles
- type
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 56
- 238000009472 formulation Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920001531 copovidone Polymers 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 206010010774 Constipation Diseases 0.000 claims description 7
- 150000002596 lactones Chemical class 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 5
- 210000001198 duodenum Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000011325 microbead Substances 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 238000011283 initial treatment period Methods 0.000 description 4
- 229960002965 pravastatin Drugs 0.000 description 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 2
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 2
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229940122601 Esterase inhibitor Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000007771 core particle Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229950003040 dalvastatin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036948P | 2014-08-13 | 2014-08-13 | |
| US62/036,948 | 2014-08-13 | ||
| US201462043789P | 2014-08-29 | 2014-08-29 | |
| US201462043649P | 2014-08-29 | 2014-08-29 | |
| US62/043,789 | 2014-08-29 | ||
| US62/043,649 | 2014-08-29 | ||
| US201562141355P | 2015-04-01 | 2015-04-01 | |
| US62/141,355 | 2015-04-01 | ||
| PCT/US2015/045140 WO2016025762A1 (en) | 2014-08-13 | 2015-08-13 | Anti-methanogenic compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528516A JP2017528516A (ja) | 2017-09-28 |
| JP2017528516A5 true JP2017528516A5 (enExample) | 2018-08-30 |
| JP6667526B2 JP6667526B2 (ja) | 2020-03-18 |
Family
ID=55301332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528760A Active JP6667526B2 (ja) | 2014-08-13 | 2015-08-13 | 抗メタン生成組成物及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9956292B2 (enExample) |
| EP (1) | EP3179983A4 (enExample) |
| JP (1) | JP6667526B2 (enExample) |
| KR (1) | KR102425303B1 (enExample) |
| CN (1) | CN106687107B (enExample) |
| AU (1) | AU2015301596B2 (enExample) |
| BR (1) | BR112017002761A2 (enExample) |
| CA (1) | CA2955666A1 (enExample) |
| IL (1) | IL250568B (enExample) |
| MX (1) | MX2017001971A (enExample) |
| RU (1) | RU2697851C2 (enExample) |
| WO (1) | WO2016025762A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014152754A2 (en) | 2013-03-15 | 2014-09-25 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9289418B2 (en) | 2013-03-15 | 2016-03-22 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9956292B2 (en) | 2014-08-13 | 2018-05-01 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| CA3254279A1 (en) | 2015-06-03 | 2025-03-18 | Triastek Inc | Dosage forms and use thereof |
| US10219518B2 (en) * | 2015-09-18 | 2019-03-05 | Environmental Intellectual Property, Inc. | Inhibition of methanogenesis to control wood boring insects and pestilence |
| WO2017200876A1 (en) * | 2016-05-19 | 2017-11-23 | Synthetic Biologics, Inc. | Anti-methanogenic compositions |
| US20200390742A1 (en) * | 2016-06-21 | 2020-12-17 | Cedars-Sinai Medical Center | Clinically efficacious anti-methanogenic compositions and uses |
| US11033490B2 (en) | 2016-12-14 | 2021-06-15 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices |
| CN110430801B (zh) * | 2016-12-14 | 2024-04-30 | 比奥拉治疗股份有限公司 | 使用tnf抑制剂治疗胃肠道疾病 |
| AU2017376801B9 (en) * | 2016-12-14 | 2024-08-01 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| AU2018212273B2 (en) * | 2017-01-26 | 2023-12-21 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| BR112019027398A2 (pt) * | 2017-06-21 | 2020-07-07 | Minerva Neurosciences, Inc. | formas de dosagem orais de liberação controlada gastrorresistente |
| US20220047855A1 (en) * | 2018-09-10 | 2022-02-17 | Argenta Innovation Limited | Sustained release formulations in delivery devices |
| JP7727623B2 (ja) * | 2019-10-09 | 2025-08-21 | アール．ピー．シェーラー テクノロジーズ，エルエルシー | 非動物性ソフトゲルカプセル製剤、その調製方法、およびその使用方法 |
| DK4037666T3 (da) | 2020-12-08 | 2024-06-24 | Ruminant Biotech Corp Ltd | Forbedring af anordninger og fremgangsmåder til indgivelse af substanser til dyr |
| EP4418992A4 (en) * | 2021-10-19 | 2025-06-25 | Cedars-Sinai Medical Center | DAILY FASTING METHANE TO DETECT METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE |
| AU2022422766A1 (en) * | 2021-12-23 | 2024-07-04 | Fonterra Co-Operative Group Limited | Use of lactic acid bacteria to improve feed efficiency |
| WO2024006531A1 (en) | 2022-07-01 | 2024-01-04 | Arkea Bio Corp. | Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems |
| WO2025036806A1 (en) * | 2023-08-15 | 2025-02-20 | Evonik Operations Gmbh | An enteric coated hard shell capsule for delivery of a dosage form in the ileum and colon |
| US12448600B2 (en) | 2023-08-24 | 2025-10-21 | Synergraze Inc. | Extraction of antimethanogenic compounds |
| US12281342B2 (en) | 2023-08-24 | 2025-04-22 | Synergraze Inc. | Extraction of antimethanogenic compounds |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US225202A (en) | 1880-03-02 | Clothes-slide | ||
| GB423083A (en) | 1934-05-22 | 1935-01-24 | Hugh Edwin Johnstone Peake | Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations |
| JPS60133852A (ja) | 1983-12-23 | 1985-07-17 | Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai | 新規な納豆製品 |
| DE3718638A1 (de) | 1987-06-04 | 1988-12-22 | Thomae Gmbh Dr K | Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPH03275630A (ja) | 1990-03-23 | 1991-12-06 | Hayashikane Sangyo Kk | 肝機能改善剤及び肝機能改善食品又は飲料 |
| US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
| DK0724454T3 (da) | 1993-10-19 | 2004-07-12 | Commw Scient Ind Res Org | Fremgangsmåde til forbedring af drövtyggerdyrs eller drövtyggerlignende dyrs udnyttelse af næringsstoffer |
| US5447850A (en) | 1994-01-31 | 1995-09-05 | Mccann; James L. | Method of producing methane from organic waste |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| EP0827402A2 (en) | 1995-05-17 | 1998-03-11 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| JP3010007B2 (ja) | 1995-05-22 | 2000-02-14 | ビオフェルミン製薬株式会社 | 配合下剤 |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| US5889038A (en) | 1996-03-20 | 1999-03-30 | Children's Hospital | Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds |
| GB9711962D0 (en) | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| CN1119154C (zh) | 1998-01-20 | 2003-08-27 | 上海信谊药业有限公司 | 双歧三联活菌制剂及制备方法 |
| US6368591B2 (en) | 1998-05-15 | 2002-04-09 | Shanghai Sine Pharmaceutical Corporation Ltd. | Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof |
| US5985907A (en) | 1998-08-12 | 1999-11-16 | Health Research, Inc. | Method for inhibiting growth of methanogens |
| US6328959B1 (en) | 1998-09-18 | 2001-12-11 | The United States Of America As Represented By The Secretary Of The Navy | Intestinal hydrogen removal using hydrogen-metabolizing microbes |
| WO2000033821A1 (en) * | 1998-12-07 | 2000-06-15 | Bristol-Myers Squibb Company | Enteric coated pravastatin bead formulation |
| NZ518707A (en) | 1999-11-03 | 2003-10-31 | Howard J | Liver selective therapy |
| AU768950B2 (en) | 1999-11-08 | 2004-01-08 | Andrx Corporation | HMG-COA reductase inhibitor extended release formulation |
| ATE338471T1 (de) | 2000-06-13 | 2006-09-15 | Unilever Nv | Nicht-lebensfähigen lactobacillus enthaltendes lebensmittelprodukt |
| US6299774B1 (en) | 2000-06-26 | 2001-10-09 | Jack L. Ainsworth | Anaerobic digester system |
| WO2003000180A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ES2535489T3 (es) | 2002-05-20 | 2015-05-12 | Cedars-Sinai Medical Center | Diagnóstico del estreñimiento por análisis de la concentración de metano |
| US10066254B2 (en) | 2002-05-20 | 2018-09-04 | Cedars-Sinai Medical Center | Diagnosis of constipation by analysis of methane concentration |
| AP2005003208A0 (en) | 2002-07-18 | 2005-03-31 | Kemira Phosphates Pty Ltd | Megasphaera elsdenii strain and its uses. |
| EP2033631A3 (en) * | 2002-09-03 | 2009-06-03 | Circ Pharma Research and Development Limited | Pravastatin pharmaceutical formulations and methods of their use |
| ZA200501508B (en) | 2002-09-03 | 2006-10-25 | Biovail Lab Inc | Pharmaceuticals formulations and methods for modified release of statin drugs |
| ITBO20020564A1 (it) | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | Bifidobatteri e preparazioni che li contengono. |
| WO2005005481A2 (en) | 2003-07-10 | 2005-01-20 | Avitek Pharma Inc. | Combination therapy for gastroenteric diseases caused by microorganisms |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| WO2005058861A1 (en) | 2003-12-16 | 2005-06-30 | Uk Chemipharm Co., Ltd. | Process for preparing simvastatin. |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| WO2005115380A2 (en) | 2004-05-27 | 2005-12-08 | Dexcel Pharma Technologies Ltd | Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins |
| US20060111436A1 (en) | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
| US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| US20100048595A1 (en) | 2005-03-23 | 2010-02-25 | Washington University In St. Louis | Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota |
| EP2079448A2 (en) * | 2006-10-10 | 2009-07-22 | Dexcel Pharma Technologies Ltd. | Improved release of statins in the intestine |
| WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
| WO2008151032A2 (en) | 2007-05-31 | 2008-12-11 | Washington University In St. Louis | Arrays and methods comprising m. smithii gene products |
| DK2170930T3 (da) * | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
| US7970905B2 (en) | 2008-07-03 | 2011-06-28 | International Business Machines Corporation | Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems |
| US20120015841A1 (en) | 2009-02-02 | 2012-01-19 | Chromocell Corporation | Novel cell lines and methods |
| UY32802A (es) | 2009-07-23 | 2011-01-31 | Provimi Holding B V | Composiciones para reducir la metanogénesis gastrointestinal en rumiantes |
| US20130230498A1 (en) | 2010-02-16 | 2013-09-05 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| CN103230593A (zh) * | 2012-10-30 | 2013-08-07 | 辽宁亿灵科创生物医药科技有限公司 | 一种治疗胃肠疾病的药物组合物 |
| EP2943213A4 (en) * | 2013-01-08 | 2016-08-17 | Jerome Schentag | ACTIVATION OF THE ENDOGENOUS HORMONE PATHWAY OF ILLEAL BRAKE FOR THE REGENERATION OF AN ORGAN AND ASSOCIATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS |
| CN103142552A (zh) * | 2013-02-22 | 2013-06-12 | 广州科的信医药技术有限公司 | 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法 |
| WO2014152754A2 (en) | 2013-03-15 | 2014-09-25 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9289418B2 (en) | 2013-03-15 | 2016-03-22 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| US9956292B2 (en) | 2014-08-13 | 2018-05-01 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| US20200390742A1 (en) | 2016-06-21 | 2020-12-17 | Cedars-Sinai Medical Center | Clinically efficacious anti-methanogenic compositions and uses |
-
2015
- 2015-08-13 US US14/826,115 patent/US9956292B2/en active Active
- 2015-08-13 AU AU2015301596A patent/AU2015301596B2/en active Active
- 2015-08-13 KR KR1020177005268A patent/KR102425303B1/ko active Active
- 2015-08-13 BR BR112017002761A patent/BR112017002761A2/pt not_active Application Discontinuation
- 2015-08-13 CN CN201580050231.6A patent/CN106687107B/zh not_active Expired - Fee Related
- 2015-08-13 MX MX2017001971A patent/MX2017001971A/es active IP Right Grant
- 2015-08-13 JP JP2017528760A patent/JP6667526B2/ja active Active
- 2015-08-13 CA CA2955666A patent/CA2955666A1/en not_active Abandoned
- 2015-08-13 RU RU2017106896A patent/RU2697851C2/ru active IP Right Revival
- 2015-08-13 EP EP15831885.7A patent/EP3179983A4/en active Pending
- 2015-08-13 WO PCT/US2015/045140 patent/WO2016025762A1/en not_active Ceased
-
2017
- 2017-02-12 IL IL250568A patent/IL250568B/en active IP Right Grant
-
2018
- 2018-03-29 US US15/940,063 patent/US10328151B2/en active Active
-
2019
- 2019-05-07 US US16/405,667 patent/US10668159B2/en active Active
-
2020
- 2020-04-27 US US16/859,082 patent/US11344501B2/en active Active
-
2022
- 2022-05-12 US US17/742,665 patent/US20230036151A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528516A5 (enExample) | ||
| RU2017106896A (ru) | Антиметаногенные композиции и их применение | |
| EP1411900B2 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | |
| DK2273985T3 (en) | Capsule for the prevention of cardiovascular diseases | |
| JP2017528431A5 (enExample) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| AU2013229990A1 (en) | Controlled-release solid dosage forms of mesalamine | |
| JP2008533127A5 (enExample) | ||
| JP2010538062A5 (enExample) | ||
| Grady et al. | Development of dexlansoprazole delayed-release capsules, a dual delayed-release proton pump inhibitor | |
| AU2005204014B2 (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
| HK1207563A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| US11717494B2 (en) | Oral solid cannabinoid oil composition for treating gastrointestinal disorders | |
| CN103957896A (zh) | 包含ω-3脂肪酸和HMG-CoA还原酶抑制剂并具有改善稳定性的口服复合制剂 | |
| CN108135882A (zh) | 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 | |
| US11696894B2 (en) | Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor | |
| CO6241106A2 (es) | Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal | |
| WO2022148672A1 (en) | Oral solid cannabinoid oil composition for treating central nervous system disorders | |
| RU2022106262A (ru) | Изделия и способы для введения терапевтических средств | |
| HK1153650A (en) | Capsule for the prevention of cardiovascular diseases |